2014
DOI: 10.1253/circj.cj-13-1579
|View full text |Cite
|
Sign up to set email alerts
|

Adipose-Derived Stem Cells Stimulate Reendothelialization in Stented Rat Abdominal Aorta

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2014
2014
2019
2019

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 30 publications
0
2
0
Order By: Relevance
“…late catch-up phenomenon rate was significantly greater in Group P than in Group N. Stent implantation per se causes persistent inflammation of the tissues around the stent, because the stent is a foreign material and it continually stretches the vascular wall. 13 The findings in this study suggested that neointimal tissue proliferation through inflammation might be promoted by IR even after DES implantation in the long-term.…”
Section: Discussionmentioning
confidence: 53%
“…late catch-up phenomenon rate was significantly greater in Group P than in Group N. Stent implantation per se causes persistent inflammation of the tissues around the stent, because the stent is a foreign material and it continually stretches the vascular wall. 13 The findings in this study suggested that neointimal tissue proliferation through inflammation might be promoted by IR even after DES implantation in the long-term.…”
Section: Discussionmentioning
confidence: 53%
“…5 Experimentally, Shiba et al recently reported that transplantation of ADRCs showed potential for not only improving cardiac function but also electrical stability in a rat model of myocardial infarction. 6 There are also a number of animal studies demonstrating the ability of ADRCs to induce angiogenesis, lymphangiogenesis, reendothelialization and cardiac regeneration in the setting of peripheral artery disease (PAD), 7 lymphedema, 8 vascular injury, 9 and ischemic heart disease. 10 The PRECISE trial was the firstin-human trial involving myocardial injection of ADRCs for chronic ischemic heart failure.…”
Section: Disclosuresmentioning
confidence: 99%